Germany’s Boehringer Ingelheim will work with Vanderbilt University to develop novel small molecules that modulate brain circuits by targeting G-protein coupled receptors (GPCRs), which could provide relief for a variety of symptoms, including memory loss, social withdrawal and the lack of motivation, they believe.
